TS-000971 — The novel disease Coronavirus, also denoted as COVID-19, was recognized by the World Health Organization as an unknown etiology in December of 2019. Severe Acute Respiratory Syndrome (SARS) is a disease that presents flu-like symptoms that is caused by coronavirus (SARS-CoV). The current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing tremendous economical, emotional, and public health burdens. A team of researchers at Nationwide Children’s Hospital have reengineered a live attenuated recombinant mumps virus to create a novel SARS-CoV-2 vaccine for infants and children under the age of twelve. As vaccination is the most effective strategy to prevent infectious diseases, this development is instrumental to the outcome of the COVID-19 pandemic.

TS-000913 — Peptides can be used to stimulate antigen-specific T cells, allowing activated T cells to be isolated from immune individuals to be used in vaccination or treatment in others. The novel disease Coronavirus, also denoted as 2019-nCoV, was recognized by the World Health Organization as an unknown etiology in December of 2019. Severe Acute Respiratory Syndrome (SARS) is a disease that presents flu-like symptoms that is caused by coronavirus (SARS-CoV). A current process widely applicable to many pathogens uses the Miltenyi Prodigy device. In a study led by Dr. Dean Lee, his team found that this process can be adapted to SARS-CoV-2 using a specialty mix of peptides to isolate T cell immunity.

TS-000855 — To diagnose urinary tract infections (UTI), the current strategies use leukocyte esterase, a urine test to look for white blood cells and other signs of infection. which have limited accuracy. These inaccuracies put patients at risk for unneeded antibiotics or delayed treatments, that can allow for UTI progression. Studies have found that the protein levels in urine could differentiate positive and negative results of UTIs. This new testing strategy can improve diagnostics and subsequent patient care.

TS-000480 — Intrabacterial pathogens are infectious bacteria that infiltrate cells and infect those that come in contact with them. Significant bacterial infections include those of salmonella, often caused by the consumption of contaminated food, and francisella, caused by handling infected animal tissue. A team at Nationwide Children’s Hospital has developed novel therapeutics to inhibit the growth of these bacteria in infected cells, designated as KH-1 and KH-2. These compounds target the host immune pathway to help the infected cell control bacterial growth, and control infections in not only antibiotic susceptible strains, but also multidrug resistance strains. Benefits: The proposed application of the compound is a novel method to control infections by intracellular pathogens. Traditional antimicrobials directly target bacteria and frequently select for antibiotic resistant mutants. Our preliminary data indicate that KH-1 does not directly kill bacteria, rather it targets the host immune pathway to help the infected cell control bacterial growth. The KH-1 is proposed for controlling infections by not only antibiotic susceptible strains but also multidrug resistance strains. Stage of Development: The use of antimicrobials to treat infections selects for antibiotic resistant mutants. Antibiotic resistance is a top threat to public's health. In the U.S alone, antibiotic resistance is responsible for more than 2 million infections and 23,000 deaths per year (CDC 2019). Novel intervention strategy is urgently needed to combat multidrug resistant strains and replace the use of antibiotics. Prototype: Intracellular pathogens use multiple mechanisms to manipulate the host cell immunity in such a way that is favorable for pathogens to grow and ultimately cause host cell death that is indicated by releasing some intracellular components from the infected host cells including lactate dehydrogenase. Host targeted-drugs protect the infected cell from death can be used as host therapy to control infections-it allows the infected host cell time to kill the ingested microbe. We screened a kinase inhibitor library for compounds that limit cell death from Salmonella infection and identified KH-1 as anti­Salmonella, and in subsequent testing, also anti-Francisella. Proof of principle: KH-1 treatment reduces host cell lysis and intracellular bacterial (Salmonella and Francisella) growth inside J774.1 macrophages. KH-1 also protects the mice from lethal Salmonella and Francisella infection. Future Work: 1- We will identify KH-1 target(s) in the host cell and investigate how KH-1 helps the infected cell to limit bacterial growth. 2- We will study any observed side effects of KH-1 to the host. 3- We will study pharmacokinetics and dynamics of KH-1. 4- We will improve KH-1 delivery to achieve the best effects. 5- We will examine the effects of KH-1 on controlling multi-drug resistant intracellular bacterial strains. Potential Applications / Potential Markets: 1- Treating infection caused by intracellular pathogens not limiting to Salmonella and Francisella. 2- Treating infections caused by multidrug resistant intracellular pathogens. Opportunity/Seeking: Commercial Partner Licensing IP Status: Patent Application Submitted

TS-000329 — There is currently no vaccine available for protecting against Zika virus (ZIKV) infection and disease. Researchers at Nationwide Children’s Hospital and The Ohio State University have developed novel candidate ZIKV vaccines that use vesicular stomatitis virus to express ZIKV proteins. The protection conferred by our vaccines does not rely on antibodies against the ZIKV envelope protein, eliminating the potential problem of antibody dependent enhancement of other species of flavivirus. Our candidate vaccines are highly attenuated while still inducing a protective immune response against ZIKV infection.